Efficacy of Ivermectin in COVID-19
Launched by COMBINED MILITARY HOSPITAL, PAKISTAN · May 17, 2020
Trial Information
Current as of May 05, 2025
Unknown status
Keywords
ClinConnect Summary
INTERVENTION It will be a randomized controlled trial which will be done on COVID-19 patients proven by PCR fulfilling the criteria (asymptomatic/mild to moderate severity). They will be divided into two groups after randomization. Group A will be administered Ivermectin single dose of 12grams along with Chloroquine as per existing hospital guidelines and group B will be given Chloroquine alone. Dose of Ivermectin to be repeated at 1 week if PCR stays negative. PCR will be done on alternate days (48, 96 and 144hours) and the duration at which the PCR becomes negative will be compared. Dose ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of signed and dated informed consent form
- • Stated willingness to comply with all study procedures and availability for the duration of the study
- • Male or female, aged 15 to 65 years
- • In good general health with no or mild to moderate symptoms of Corona virus disease
- • PCR positive for SARS-Cov-2.
- • Ability to take oral medication and be willing to adhere to the drug intake regimen
- Exclusion Criteria:
- • Severe symptoms likely attributed to Cytokine Release Storm.
- • Malignant diseases, diabetes mellitus, chronic kidney disease and cirrhosis liver with CPT class B or C.
About Combined Military Hospital, Pakistan
The Combined Military Hospital (CMH) in Pakistan is a premier healthcare institution dedicated to providing advanced medical services and fostering innovative research in the field of military and civilian healthcare. As a leading clinical trial sponsor, CMH is committed to enhancing medical knowledge and improving patient outcomes through rigorous clinical research protocols. The hospital boasts a team of experienced professionals, state-of-the-art facilities, and a robust ethical framework, ensuring the highest standards of safety and compliance in all clinical trials. CMH's strategic focus on collaboration and excellence positions it as a key player in the advancement of medical science and therapeutic development in Pakistan and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahore, Punjab, Pakistan
Patients applied
Trial Officials
Karamat Hu Bukhari, FCPS MED
Study Director
Combined military hospital lahore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials